JP2005530486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530486A5 JP2005530486A5 JP2003571297A JP2003571297A JP2005530486A5 JP 2005530486 A5 JP2005530486 A5 JP 2005530486A5 JP 2003571297 A JP2003571297 A JP 2003571297A JP 2003571297 A JP2003571297 A JP 2003571297A JP 2005530486 A5 JP2005530486 A5 JP 2005530486A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- pharmaceutical composition
- oligonucleotide
- trpm
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/080,794 US6900187B2 (en) | 1999-02-26 | 2002-02-22 | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| PCT/US2003/005305 WO2003072591A1 (en) | 2002-02-22 | 2003-02-20 | Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530486A JP2005530486A (ja) | 2005-10-13 |
| JP2005530486A5 true JP2005530486A5 (https=) | 2006-04-06 |
Family
ID=27765243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571297A Abandoned JP2005530486A (ja) | 2002-02-22 | 2003-02-20 | ２’−ｏ−（２−メトキシ）エチル修飾を有するオリゴヌクレオチドを使用するｔｒｐｍ−２アンチセンス療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6900187B2 (https=) |
| EP (1) | EP1485401A4 (https=) |
| JP (1) | JP2005530486A (https=) |
| KR (1) | KR20040088514A (https=) |
| AU (1) | AU2003213190A1 (https=) |
| CA (1) | CA2475433A1 (https=) |
| HU (1) | HUP0500041A3 (https=) |
| NO (1) | NO20043953L (https=) |
| NZ (1) | NZ534490A (https=) |
| WO (1) | WO2003072591A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| KR100768109B1 (ko) | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| AU2003237616B2 (en) * | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| NZ538288A (en) * | 2002-08-21 | 2008-04-30 | Univ British Columbia | Treatment of melanoma by reduction in clusterin levels |
| EP1578767A4 (en) * | 2002-12-04 | 2008-01-09 | Algos Therapeutics Inc | METHOD AND MATERIALS FOR MODULATING TRPM2 |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| EP2397563A3 (en) * | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
| AU2006291990B2 (en) * | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| BRPI0616370A2 (pt) * | 2005-09-19 | 2011-06-14 | Johnson & Johnson Pharmaceutical Res & Dev L L C | modulaÇço da expressço de receptor de glucocorticàide |
| EP1971371B1 (en) * | 2005-12-01 | 2015-08-05 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| CA2631677C (en) | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| JP5746968B2 (ja) * | 2008-07-18 | 2015-07-08 | オンコジェネックス・テクノロジーズ・インコーポレーテッド | アンチセンス製剤 |
| AU2008359989A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
| EP2451969A2 (en) | 2009-07-07 | 2012-05-16 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| CN102666585B (zh) | 2009-11-24 | 2015-02-18 | 阿莱斯亚生物疗法股份有限公司 | 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途 |
| WO2012123823A1 (en) * | 2011-03-15 | 2012-09-20 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| WO2013123588A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| SMT201700339T1 (it) * | 2012-04-23 | 2017-09-07 | Biomarin Tech Bv | Oligonucleotidi di modulazione dell'rna con caratteristiche migliorate per il trattamento dei disturbi neuromuscolari |
| UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
| WO2014100602A1 (en) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Treatment of egf-receptor dependent pathologies |
| PT3049085T (pt) | 2013-09-26 | 2021-10-01 | Beth Israel Deaconess Medical Ct Inc | Inibidores de sgk1 no tratamento da síndrome do qt longo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| JPH11143729A (ja) * | 1997-11-07 | 1999-05-28 | Nec Corp | フォールトトレラントコンピュータ |
| US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| KR100768109B1 (ko) | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| MXPA02006167A (es) | 1999-12-21 | 2004-02-26 | Univ Yale | Promocion de la angiogenesis con survivina. |
| US20020132350A1 (en) | 2000-09-14 | 2002-09-19 | Pioneer Hi-Bred International, Inc. | Targeted genetic manipulation using Mu bacteriophage cleaved donor complex |
| AU2003237616B2 (en) | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
-
2002
- 2002-02-22 US US10/080,794 patent/US6900187B2/en not_active Expired - Fee Related
-
2003
- 2003-02-20 JP JP2003571297A patent/JP2005530486A/ja not_active Abandoned
- 2003-02-20 HU HU0500041A patent/HUP0500041A3/hu unknown
- 2003-02-20 WO PCT/US2003/005305 patent/WO2003072591A1/en not_active Ceased
- 2003-02-20 CA CA002475433A patent/CA2475433A1/en not_active Abandoned
- 2003-02-20 AU AU2003213190A patent/AU2003213190A1/en not_active Abandoned
- 2003-02-20 EP EP03709236A patent/EP1485401A4/en not_active Withdrawn
- 2003-02-20 NZ NZ534490A patent/NZ534490A/en unknown
- 2003-02-20 KR KR10-2004-7013102A patent/KR20040088514A/ko not_active Withdrawn
-
2004
- 2004-09-21 NO NO20043953A patent/NO20043953L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530486A5 (https=) | ||
| JP4785252B2 (ja) | Ｔｒｐｍ−２アンチセンス療法 | |
| US20160168577A1 (en) | Clusterin Antisense Therapy for Treatment of Cancer | |
| JP2003503309A5 (https=) | ||
| US5744460A (en) | Combination for treatment of proliferative diseases | |
| US7795232B1 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
| JP2018529732A5 (https=) | ||
| Nuno Moreira et al. | Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality | |
| AU2001288373A1 (en) | Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers | |
| JP2018530325A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| US6080727A (en) | Oligonucleotide treatments and compositions for human melanoma | |
| KR101052289B1 (ko) | 클러스테린 양의 감소에 의한 흑색종의 치료 | |
| JP2019500334A (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 | |
| JP2006502243A5 (https=) | ||
| JP2006503904A5 (https=) | ||
| CN115176008A (zh) | 用于抑制FoxP3表达的修饰反义寡核苷酸 | |
| JP5406024B2 (ja) | Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法 | |
| CA2421087A1 (en) | Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy | |
| WO2004056971A2 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
| Benner et al. | Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies | |
| Nakamura et al. | Antisense oligonucleotide for tissue factor inhibits hepatic ischemic reperfusion injury | |
| JP7766375B2 (ja) | 変形されたｒｔ－ｌｅｔ７を有効成分として含む肝癌の予防または治療用組成物 | |
| Yacyshyn et al. | Making sense of antisense |